story of the week
Risks of Cardiovascular Events and Mortality Are Lower With Dapagliflozin Than With DPP-4 Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dapagliflozin Is Associated With Lower Risk of Cardiovascular Events and All-Cause Mortality in People With Type 2 Diabetes (CVD-REAL Nordic) When Compared With Dipeptidyl Peptidase-4 Inhibitor Therapy: A Multinational Observational Study
Diabetes Obes Metab 2017 Sep 08;[EPub Ahead of Print], F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, M Thuresson, P Fenici, D Nathanson, JW Eriksson, A Norhammar, J Bodegard, KI BirkelandFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.